Eravacycline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Eravacycline: From Complicated Intra-Abdominal Infections to Bronchitis
One-Sentence Summary
Eravacycline (Xerava) is a novel fluorocycline antibiotic approved by the FDA for complicated intra-abdominal infections (cIAI), belonging to the tetracycline class with broad-spectrum antibacterial activity. The TxGNN model predicts it may be effective for Bronchitis, with a prediction score of 96.85%. Currently, no clinical trials and no published literature specifically examine eravacycline for bronchitis, placing this candidate at evidence level L5 — hypothesis generation only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Complicated intra-abdominal infections (cIAI) — not registered in Singapore |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 96.85% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Research Question |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Eravacycline is a first-in-class fluorocycline antibiotic that inhibits bacterial protein synthesis by binding to the bacterial 30S ribosomal subunit, blocking aminoacyl-tRNA attachment and halting translation. It demonstrates broad-spectrum activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria — including multidrug-resistant strains such as MRSA and carbapenem-resistant Enterobacteriaceae.
The mechanistic rationale for bronchitis is biologically plausible in a specific subset of patients. Bacterial bronchitis — particularly cases caused by atypical pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp., and Haemophilus influenzae — falls squarely within eravacycline's demonstrated antibacterial spectrum. The tetracycline class (e.g., doxycycline) is already a guideline-recommended option for atypical respiratory tract infections, and eravacycline shares the same core inhibitory mechanism at the 30S ribosomal level.
However, a critical caveat must be acknowledged: acute bronchitis is viral in origin in more than 90% of cases, where antibiotics confer no meaningful clinical benefit. The repurposing opportunity, if one exists, is limited to the culture-confirmed or biomarker-selected bacterial/atypical pathogen subgroup. Any development programme would need to define this subpopulation rigorously before proceeding.
Clinical Trial Evidence
Currently no related clinical trials registered for Eravacycline + Bronchitis.
Literature Evidence
Currently no related literature available for Eravacycline + Bronchitis.
Singapore Market Information
Eravacycline is not currently registered or marketed in Singapore. No Health Sciences Authority (HSA) product authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: The TxGNN model assigns a high prediction score (96.85%) for eravacycline in bronchitis, and the mechanistic connection to atypical/bacterial bronchitis subpopulations is biologically coherent. However, the complete absence of clinical trial or published literature evidence for this specific use case — combined with the predominantly viral (non-antibiotic-amenable) etiology of bronchitis — means this remains a hypothesis that requires basic evidence generation before any investment or development decision.
To proceed, the following is needed:
- Mechanism clarification: Retrieve full MOA data from DrugBank (DB12329), particularly eravacycline's activity profile against respiratory atypical pathogens (Mycoplasma, Chlamydia, Legionella)
- Indirect evidence review: Conduct a systematic literature search for eravacycline in community-acquired pneumonia (CAP) or atypical respiratory infections, which would provide adjacent mechanistic support
- Pharmacokinetic assessment: Evaluate respiratory tract penetration (sputum, bronchial mucosa concentrations) from existing cIAI pharmacokinetic data
- Subpopulation definition: Propose a target patient population (e.g., culture-confirmed atypical bacterial bronchitis) with appropriate biomarker or microbiological entry criteria
- Preclinical signal: Consider an in vitro/in vivo respiratory infection model study as a prerequisite before any clinical hypothesis testing
- Singapore regulatory landscape: Confirm whether any HSA-approved tetracyclines are indicated for respiratory infections, to establish the competitive and regulatory baseline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.